Literature DB >> 25105705

Optimizing dosing of oncology drugs.

L Minasian1, O Rosen2, D Auclair3, A Rahman4, R Pazdur4, R L Schilsky5.   

Abstract

The purpose of this article is to acknowledge the challenges in optimizing the dosing of oncology drugs and to propose potential approaches to address these challenges in order to optimize effectiveness, minimize toxicity, and promote adherence in patients. These approaches could provide better opportunities to understand the sources of variability in drug exposure and clinical outcomes during the development and premarketing evaluation of investigational new drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25105705     DOI: 10.1038/clpt.2014.153

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

2.  Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.

Authors:  Shing M Lee; Daniel Backenroth; Ying Kuen Ken Cheung; Dawn L Hershman; Diana Vulih; Barry Anderson; Percy Ivy; Lori Minasian
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

Review 3.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

4.  Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis.

Authors:  Asbjørn Nøhr-Nielsen; Theis Lange; Julie Lyng Forman; Theodoros Papathanasiou; David J R Foster; Richard N Upton; Ole Jannik Bjerrum; Trine Meldgaard Lund
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

5.  Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Authors:  Cody Chiuzan; Jonathan Shtaynberger; Gulam A Manji; Jimmy K Duong; Gary K Schwartz; Anastasia Ivanova; Shing M Lee
Journal:  J Biopharm Stat       Date:  2017-02-06       Impact factor: 1.051

Review 6.  Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.

Authors:  Rajendar K Mittapalli; Cen Guo; Stefanie K Drescher; Donghua Yin
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-14       Impact factor: 3.288

7.  Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).

Authors:  Anne L Loeser; Lucy Gao; Aditya Bardia; Mark E Burkard; Kevin M Kalinsky; Jeffrey Peppercorn; Hope S Rugo; Martha Carlson; Janice Cowden; Lesley Glenn; Julia Maues; Sheila McGlown; Andy Ni; Natalia Padron; Maryam Lustberg
Journal:  Breast Cancer Res Treat       Date:  2022-10-06       Impact factor: 4.624

8.  Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.

Authors:  Yan Ji; Pai-Hsi Huang; Steve Woolfenden; Andrea Myers
Journal:  Clin Transl Sci       Date:  2022-05-27       Impact factor: 4.438

Review 9.  Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?

Authors:  Geoffrey Alan Watson; Jeffrey Doi; Aaron Richard Hansen; Anna Spreafico
Journal:  Br J Clin Pharmacol       Date:  2020-06-13       Impact factor: 4.335

Review 10.  Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology.

Authors:  Belén P Solans; María Jesús Garrido; Iñaki F Trocóniz
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.